Sarcoidosis

Current Opinion in Ophthalmology

Volumn 18, Issue 6, 2007, Pages 470-475

  Margolis, Ron ^a   Lowder, Careen Y ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Diagnosis; Epidemiology; Genetics; Immunology; Sarcoidosis; Treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYTOKINE; ETANERCEPT; FLUORODEOXYGLUCOSE F 18; INFLIXIMAB; LEFLUNOMIDE; LEUKOCYTE ANTIGEN; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; ENVIRONMENTAL EXPOSURE; EYE BIOPSY; EYE INFLAMMATION; EYE SARCOIDOSIS; GENE FUNCTION; GENETIC SUSCEPTIBILITY; GENOME; GRANULOMA; HEREDITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNE RESPONSE; IMMUNITY; OCCUPATIONAL EXPOSURE; OPTIC NERVE DISEASE; PATIENT SELECTION; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; RETINA VASCULITIS; REVIEW; SARCOIDOSIS; AFRICAN AMERICAN; ETHNOLOGY; EYE DISEASE; GENETIC PREDISPOSITION; HOSPITALIZATION; INCIDENCE; PATHOLOGY; PATHOPHYSIOLOGY;

AFRICAN AMERICANS; EYE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX;

EID: 38449119555     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3282f06c6c     Document Type: Review

References (79)

1. Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005; 201:755-767.
2. Eishi Y, Suga M, Ishige I, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 2002; 40:198-204.
3. Yasuhara T, Tada R, Nakano Y, et al. The presence of Propionibacterium spp. in the vitreous fluid of uveitis patients with sarcoidosis. Acta Ophthalmol Scand 2005; 83:364-369.
4. Muller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J 2006; 27:1190-1195.
5. Heffner DK. The cause of sarcoidosis: the Centurial enigma solved. Ann Diagn Pathol 2007; 11:142-152. This is an interesting commentary on the possible etiologic agents involved in the pathogenesis of sarcoidosis from a pathologist's point of view.
6. Kucera GP, Rybicki BA, Kirkey KL, et al. Occupational risk factors for sarcoidosis in African-American siblings. Chest 2003; 123:1527-1535.
7. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170:1324-1330.
8. Kajdasz DK, Lackland DT, Mohr LC, Judson MA. A current assessment of rurally linked exposures as potential risk factors for sarcoidosis. Ann Epidemiol 2001; 11:111-117.
9. Rybicki BA, Amend KL, Maliarik MJ, Iannuzzi MC. Photocopier exposure and risk of sarcoidosis in African-American sibs. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:49-55.
10. Gorham ED, Garland CF, Garland FC, et al. Trends and occupational associations in incidence of hospitalized pulmonary sarcoidosis and other lung diseases in Navy personnel: a 27-year historical prospective study, 1975-2001. Chest 2004; 126:1431-1438.
11. Barnard J, Rose C, Newman L, et al. Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med 2005; 47:226-234.
12. Prezant DJ, Dhala A, Goldstein A, et al. The incidence, prevalence, and severity of sarcoidosis in New York City firefighters. Chest 1999; 116:1183-1193.
13. Ota M, Amakawa R, Uehira K, et al. Involvement of dendritic cells in sarcoidosis. Thorax 2004; 59:408-413.
14. Zissel G, Prasse A, Muller-Quernheim J. Sarcoidosis: immunopathogenetic concepts. Semin Respir Crit Care Med 2007; 28:3-14. This is an excellent review and update of the immune processes involved in the pathogenesis of sarcoidosis.
15. Rybicki BA, Sinha R, Iyengar S, et al. Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study. Genes Immun 2007; 8:379-386.
16. Baumer I, Zissel G, Schlaak M, Muller-Quernheim J. Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1997; 16:171-177.
17. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203:359-370.
18. Capelli A, Di Stefano A, Lusuardi M, et al. Increased macrophage inflammatory protein-1alpha and macrophage inflammatory protein-1beta levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis. Am J Respir Crit Care Med 2002; 165:236-241.
19. Fehrenbach H, Zissel G, Goldmann T, et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J 2003; 21:421-428.
20. Mrazek F, Holla LI, Hutyrova B, et al. Association of tumour necrosis factoralpha, lymphotoxin-alpha and HLA-DRB1 gene polymorphisms with Lofgren's syndrome in Czech patients with sarcoidosis. Tissue Antigens 2005; 65:163-171.
21. Dai H, Guzman J, Chen B, Costabel U. Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 2005; 127:251-256.
22. Kieszko R, Krawczyk P, Chocholska S, et al. Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis. Respir Med 2007; 101:645-654.
23. Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001; 166:642-649.
24. Oltmanns U, Schmidt B, Hoernig S, et al. Increased spontaneous interleukin-10 release from alveolar macrophages in active pulmonary sarcoidosis. Exp Lung Res 2003; 29:315-328.
25. Salmeri FM, Sofo V, Ando FG, et al. Imbalance of serum cytokine network in sarcoid patients: index of sarcoidosis relapse? Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:53-61.
26. Larousserie F, Pflanz S, Coulomb-L'Hermine A, et al. Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 2004; 202:164-171.
27. Wysoczanska B, Bogunia-Kubik K, Suchnicki K, et al. Combined association between IFN-gamma 3,3 homozygosity and DRB*103 in Lofgren's syndrome patients. Immunol Lett 2004; 91:127-131.
28. Takeuchi M, Oh IK, Suzuki J, et al. Elevated serum levels of CXCL9/monokine induced by interferon-gamma and CXCL10/interferon-gamma-inducible protein-10 in ocular sarcoidosis. Invest Ophthalmol Vis Sci 2006; 47: 1063-1068.
29. ACCESS Research Group. Design of a case control etiologic study of sarcoidosis (ACCESS). J Clin Epidemiol. 1999 Dec; 52:1173-1186.
30. Semenzato G. ACCESS: A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:83-86.
31. Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med 2007; 28:22-35.
32. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164:2085-2091.
33. Grunewald J, Eklund A, Olerup O. Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med 2004; 169:696-702.
34. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB11101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003; 73:720-735.
35. Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Crit Care Med 2003; 167:1225-1231.
36. Rybicki BA, Hirst K, Iyengar SK, et al. A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:115-122.
37. Gray-McGuire C, Sinha R, Iyengar S, et al. Genetic characterization and fine mapping of susceptibility loci for sarcoidosis in African Americans on chromosome 5. Hum Genet 2006; 120:420-430.
38. Schurmann M, Reichel P, Muller-Myhsok B, et al. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med 2001; 164:840-846.
39. Li Y, Wollnik B, Pabst S, et al. BTNL2 gene variant and sarcoidosis. Thorax 2006; 61:273-274.
40. Yamaguchi K, Nakajima H, Azuma H, et al. Diagnosis of ocular sarcoidosis by diagnostic criteria for systemic sarcoidosis [in Japanese]. Nippon Ganka Gakkai Zasshi 2004; 108:98-102.
41. Lynch JP 3rd. Computed tomographic scanning in sarcoidosis. Semin Respir Crit Care Med 2003; 24:393-418.
42. Kaiser PK, Lowder CY, Sullivan P, et al. Chest computerized tomography in the evaluation of uveitis in elderly women. Am J Ophthalmol 2002; 133:499-505.
43. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736-755.
44. Lury KM, Smith JK, Matheus MG, Castillo M. Neurosarcoidosis: review of imaging findings. Semin Roentgenol 2004; 39:495-504.
45. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart 2006; 92:282-288.
46. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26:1538-1543.
47. Judson MA, Hirst K, Iyengar SK, et al. Comparison of sarcoidosis phenotypes among affected African-American siblings. Chest 2006; 130:855-862.
48. Annema JT, Veselic M, Rabe KF. Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of sarcoidosis. Eur Respir J 2005; 25:405-409.
49. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10 Pt 1):1885-1889.
50. Bonfioli AA, Orefice F. Sarcoidosis. Semin Ophthalmol 2005; 20:177-182.
51. Bradley D, Baughman RP, Raymond L, Kaufman AH. Ocular manifestations of sarcoidosis. Semin Respir Crit Care Med 2002; 23:543-548.
52. Drent M, Bomans PH, Van Suylen RJ, et al. Association of man-made mineral fibre exposure and sarcoidlike granulomas. Respir Med 2000; 94:815-820.
53. Evans M, Sharma O, LaBree L, et al. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis. Ophthalmology 2007; 114:325-333. This was an interesting study of the prevalence of ocular manifestations in African American and Caucasian patients with biopsy-proven sarcoidosis, and of the relationship between ACE levels, chest radiograph findings, and ocular signs.
54. Wertheim MS, Mathers WD, Suhler EB, et al. Histopathological features of conjunctival sarcoid nodules using noninvasive in vivo confocal microscopy. Arch Ophthalmol 2005; 123:274-276.
55. Chung YM, Lin YC, Huang DF, et al. Conjunctival biopsy in sarcoidosis. J Chin Med Assoc 2006; 69:472-477.
56. Cassoux N, Charlotte F, Rao NA, et al. Endoretinal biopsy in establishing the diagnosis of uveitis: a clinicopathologic report of three cases. Ocul Immunol Inflamm 2005; 13:79-83.
57. Saito W, Kotake S, Ohno S. A patient with sarcoidosis diagnosed by a biopsy of scleral nodules. Graefes Arch Clin Exp Ophthalmol 2005; 243:374-376.
58. Khalatbari D, Stinnett S, McCallum RM, Jaffe GJ. Demographic-related variations in posterior segment ocular sarcoidosis. Ophthalmology 2004; 111:357-362.
59. Coker RK. Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis. Drugs 2007; 67:1139-1147.
60. Chan WM, Lim E, Liu DT, et al. Intravitreal triamcinolone acetonide for choroidal granuloma in sarcoidosis. Am J Ophthalmol 2005; 139:1116-1118.
61. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:60-66.
62. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002; 8:470-476.
63. Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2003; (3):CD003536.
64. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:43-48.
65. Baughman RP, Ohmichi M, Lower EE. Combination therapy for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:133-137.
66. Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:185-190.
67. Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 2003; 17:425-431.
68. Baughman RP, Lower EE. Novel therapies for sarcoidosis. Semin Respir Crit Care Med 2007; 28:128-133. This is an excellent update on current drugs used in the treatment of systemic sarcoidosis.
69. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177-185.
70. Verschueren K, Van Essche E, Verschueren P, et al. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 2007; 6 Mar [Epub ahead of print].
71. Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, et al. Development of sarcoidosis during etanercept therapy. Arthritis Rheum 2006; 55:817-820.
72. Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128:1062-1147.
73. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795-802.
74. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005; 43:7-11.
75. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123:903-912.
76. Katz JM, Bruno MK, Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 2003; 60:426-430.
77. Salama B, Gicquel JJ, Lenoble P, Dighiero PL. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol 2006; 41:766-768.
78. Cruz BA, Reis DD, Araujo CA. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int 2007; 23 May [Epub ahead of print].
79. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-426.